Latest Conference Articles

February 9th 2018, 3:40am

Genitourinary Cancers Symposium (ASCO GU)

Monika Joshi, MD, assistant professor, Penn State Hershey Medical Center, discusses a phase Ib study of durvalumab (Imfinzi) and radiation therapy (DUART) followed by adjuvant durvalumab in patients with urothelial carcinoma.

February 6th 2018, 3:00am

Genitourinary Cancers Symposium (ASCO GU)

A new model based on 6 clinical factors may be able to predict overall survival for patients with advanced urothelial cancers being treated with the PD-L1 inhibitor atezolizumab.

February 6th 2018, 3:00am

Genitourinary Cancers Symposium (ASCO GU)

The addition of docetaxel (Taxotere) to frontline long-term hormone therapy for advanced prostate cancer improved quality of life and reduced the need for subsequent therapy, contributing to lower overall costs in the nonmetastatic setting.

February 6th 2018, 3:00am

Genitourinary Cancers Symposium (ASCO GU)

Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer, according to findings from the phase III SPARTAN trial.

February 6th 2018, 3:00am

Genitourinary Cancers Symposium (ASCO GU)

The combination of atezolizumab and bevacizumab reduced the risk of progression or death by 26% compared with sunitinib for patients with untreated PD-L1–positive metastatic renal cell carcinoma.

February 6th 2018, 3:00am

Genitourinary Cancers Symposium (ASCO GU)

Treatment with the combination of enzalutamide and androgen deprivation therapy reduced the risk of metastases or death by 71% compared with ADT alone in patients with nonmetastatic castration-resistant prostate cancer.

January 21st 2018, 3:23am

Gastrointestinal Cancers Symposium (ASCO GI)

Treatment with the PD-1 inhibitor pembrolizumab elicited promising progression-free survival and overall survival results in patients with advanced hepatocellular carcinoma who received previous treatment with sorafenib.

January 21st 2018, 2:20am

Gastrointestinal Cancers Symposium (ASCO GI)

Sequencing regorafenib before cetuximab showed superior overall survival compared with the reverse sequence in patients with metastatic colorectal cancer following failure of standard chemotherapy.

January 21st 2018, 12:28am

Gastrointestinal Cancers Symposium (ASCO GI)

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the updated findings from CheckMate-142 in metastatic colorectal cancer during the 2018 Gastrointestinal Cancers Symposium.

January 21st 2018, 12:26am

Gastrointestinal Cancers Symposium (ASCO GI)

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the CELESTIAL trial in advanced hepatocellular carcinoma during the 2018 Gastrointestinal Cancers Symposium.

January 20th 2018, 10:30pm

Gastrointestinal Cancers Symposium (ASCO GI)

Induction treatment with nab-paclitaxel plus gemcitabine demonstrated a time to treatment failure of 8.8 months for patients with newly diagnosed locally advanced pancreatic cancer.

January 20th 2018, 3:52am

Gastrointestinal Cancers Symposium (ASCO GI)

Tanios Bekaii-Saab, MD, discusses the results and significance of the ReDOS study in metastatic colorectal cancer, as well as shared some insight on the Reverce trial.

January 20th 2018, 3:18am

Gastrointestinal Cancers Symposium (ASCO GI)

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study of entrectinib in patients with pancreas cancer.

January 20th 2018, 3:18am

Gastrointestinal Cancers Symposium (ASCO GI)

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, Univeristy of Chicago Medicine, discusses margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) as treatment for patients with advanced HER2-positive gastroesophageal junction (GEJ) or gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

January 20th 2018, 3:01am

Gastrointestinal Cancers Symposium (ASCO GI)

The CellMax biomimetic platform, a novel circulating tumor cell assay, was 84% to 88% accurate at detecting precancerous and cancerous colorectal lesions.

January 19th 2018, 11:29pm

Gastrointestinal Cancers Symposium (ASCO GI)

Nivolumab alone and in combination with ipilimumab induced responses in patients with heavily pretreated gastrointestinal stromal tumor.

January 19th 2018, 10:03pm

Gastrointestinal Cancers Symposium (ASCO GI)

Adding ramucirumab to standard first-line chemotherapy significantly improved investigator-assessed progression-free survival compared with chemotherapy plus placebo in treatment-naive patients with HER2-negative gastric cancer.

January 19th 2018, 8:08am

Gastrointestinal Cancers Symposium (ASCO GI)

Maria Svensson, MD, Lund University, discusses the associations of PD-1 and PD-L1 expression with mismatch repair (MMR) status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

January 19th 2018, 8:07am

Gastrointestinal Cancers Symposium (ASCO GI)

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses a phase II study of nivolumab (Opdivo) in patients with metastatic unresectable gastrointestinal stromal tumors (GIST) during the 2018 Gastrointestinal Cancers Symposium.

January 19th 2018, 4:08am

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of the VEGFR-2 inhibitor ramucirumab plus the anti-PD-L1 agent durvalumab demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.